


# HPV

## PREVENTION AND CONTROL BOARD

Visit our website

[www.hpvboard.org](http://www.hpvboard.org)



# Aims & Objectives

## Aim

- To contribute to the prevention and control of HPV and HPV related diseases
- To generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders

## Objectives

- Provide evidence-based guidance on key technical and strategic issues by organizing two meetings per year i.e., 1) technical meeting and 2) country meeting
- Monitor the progress of HPV control programs at the country and regional levels.



# HPV Board Secretariat

- Personnel involved\*:

- Alex Vorsters
- Brenda Janssens
- Dur-e-Nayab Waheed
- Ricardo Burdier
- Xenia Mikulla
- Greet Hendrickx
- Sara Valckx
- Sakshi Jindal

- Executive Secretary: Alex Vorsters




- Located within the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp

*\*: Total involvement of 2.0 FTE, all member have other tasks at the department.*



# Secretariat Activities

- Preparation and organisation of meetings
  - Publications
  - Media activities
  - Website: [www.hpvboard.org](http://www.hpvboard.org)
  - Participation in third party meetings
  - All financial issues are done by the rules of the University of Antwerp
-  Permanent intensive communication between HPV board members and secretariat



# A multi-disciplinary Board formed by prominent experts

- Act in their personal capacity
- Are often affiliated with stakeholding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president i.e., minimal bureaucratic structure

---

## Advisors

---

- **Dr. Alex Vorsters**
  - *University of Antwerp, Belgium*
- **Prof. Dr. Anna Giuliano**
  - *Moffitt Cancer Center, USA*
- **Prof. Dr. Eduardo Franco**
  - *McGill University, Canada*
- **Dr. Heidi Larson**
  - *London School of Hygiene and Tropical Medicine, UK*
- **Dr. Kate Cuschieri**
  - *Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Scotland, UK*
- **Prof. Mamadou Diop**
  - *Joliot Curie Cancer institute of Dakar, Senegal*
- **Dr. Marc Arbyn**
  - *Scientific Institute of Public Health, Belgium*
- **Dr. Mark Kane**
  - *Consultant USA*
- **Prof. Dr. Mario Poljak**
  - *Institute of Microbiology and Immunology, clinical Microbiology, Slovenia*
- **Prof. Dr. Margaret Stanley**
  - *University of Cambridge, UK*



# A multi-disciplinary Board formed by prominent experts

## Advisors

- **Prof. dr. Mira Kojouharova**
  - *National Centre of Infectious and Parasitic Diseases (NCIPD), Bulgaria*
- **Prof. Dr. Narendra Kumar Arora**
  - *The INCLEN Trust International*
- **Prof. dr. Nubia Muñoz**
  - *The National Cancer Institute of Colombia*
- **Prof. Dr. Pierre Van Damme**
  - *University of Antwerp, Belgium*
- **Prof. Dr. Paolo Bonanni**
  - *University of Florence, Italy*
- **Dr. Silvia de Sanjosé**
  - *Catalan Institute of Oncology (ICO), Spain*
- **Dr. Sharon Hanley**
  - *Hokkaido University, Japan*
- **Prof. Dr. Susanne Krüger Kjaer**
  - *University of Copenhagen, Denmark*

- **Prof. Suzanne Garland**
  - *University of Melbourne, Australia*
- **Dr. Xavier Bosch**
  - *Catalan Institute of Oncology (ICO), Spain*
- **Dr. Nelly Mugo**
  - *Kenya Medical Research Institute*

## Observers

- Dr. Iacobo Baussano, IACR
- Dr. Nedret Emiroglu, WHO Euro
- Mr. Tarik Derrough, ECDC
- Dr. Liudmila Mosina , WHO Euro
- Dr. Lauri Markowitz, CDC, USA
- Rebecca Casey, CDC, USA.







 HPV Prevention  
and Control Board

 University  
of Antwerp



EFFECTIVENESS  
AND REAL-WORLD  
DATA ON HPV  
VACCINATION




14TH HPV  
PREVENTION AND  
CONTROL BOARD  
MEETING

ANTWERP,  
BELGIUM

1-2 JUNE, 2023



SELF-SAMPLING  
AS A SCREENING  
AND SAMPLING  
TOOL



EFFECTIVE  
COMMUNICATION  
FOR CERVICAL  
CANCER  
PREVENTION  
PROGRAMS



# Publications in Scientific Journals

## Papillomavirus Research:

Manuscript on ‘Overcoming barriers in HPV vaccination and screening programs’

## Vaccine:

HPV Immunization programs: Ensuring their sustainability and resilience.

## Papilloma Virus Research:

The Role of healthcare providers in HPV Vaccination Programs- A meeting report



Papillomavirus Research  
Volume 4, December 2017, Pages 45-53  
[open access](#)



### Overcoming barriers in HPV vaccination and screening programs

Alex Vorsters <sup>a</sup> ✉, Marc Arbyn <sup>b</sup>, Marc Baay <sup>c</sup>, Xavier Bosch <sup>d</sup>, Silvia de Sanjosé <sup>d, e</sup>, Sharon Hanley <sup>f</sup>, Emilie Karafillakis <sup>g</sup>, Pier Luigi Lopalco <sup>h</sup>, Kevin G. Pollock <sup>i</sup>, Joanne Yarwood <sup>j</sup>, Pierre Van Damme <sup>a</sup>

Vaccine 36 (2018) 5219–5221



Contents lists available at ScienceDirect  
Vaccine  
journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)



Commentary

HPV immunization programs: Ensuring their sustainability and resilience

Alex Vorsters <sup>\*</sup>, Pierre Van Damme

*Centre for the Evaluation of Vaccination, University of Antwerp, Belgium*



Papillomavirus Research  
Volume 8, December 2019, 100183



The role of healthcare providers in HPV vaccination programs – A meeting report



# Publications in Scientific Journals

## BMC Proceedings:

Prevention and control of HPV infection and HPV-related cancers in Colombia.

Vorsters et al. *BMC Proceedings* 2020, **14**(Suppl 9):8  
<https://doi.org/10.1186/s12919-020-00192-2>

BMC Proceedings

MEETING REPORT

Open Access

## Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report



Alex Vorsters<sup>1\*</sup>, Francesc Xavier Bosch<sup>2,3</sup>, Paolo Bonanni<sup>4</sup>, Eduardo L. Franco<sup>5</sup>, Marc Baay<sup>6</sup>, Clarissa Simas<sup>7</sup>, Dur-e-Nayab Waheed<sup>1</sup>, Carlos Castro<sup>8</sup>, Raul Murillo<sup>9</sup>, Lina Trujillo<sup>10</sup>, Carolina Wiesner<sup>10</sup> and Nubia Muñoz<sup>10</sup>

From Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward Bogota, Colombia. 15-16 November 2018

## Acta Dermatovenerologica

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Acta Dermatovenerol APA

Acta Dermatovenerologica  
Alpina, Pannonica et Adriatica

2021;30:21-26  
doi: 10.15570/actaapa.2021.5

## Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Mario Poljak<sup>1</sup>, Kate Cuschieri<sup>2</sup>, Dur-e-Nayab Waheed<sup>3</sup>, Marc Baay<sup>4</sup>, Alex Vorsters<sup>3,5</sup>

<sup>1</sup>Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. <sup>2</sup>Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian Scotland, Edinburgh, United Kingdom. <sup>3</sup>Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Wilrijk, Belgium. <sup>4</sup>P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.



# Publications in Scientific Journals

Preventive Medicine 156 (2022) 106960



ELSEVIER

Contents lists available at [ScienceDirect](#)

Preventive Medicine

journal homepage: [www.elsevier.com/locate/ypmed](http://www.elsevier.com/locate/ypmed)



## HPV prevention and control – The way forward

Alex Vorsters<sup>a,\*</sup>, F. Xavier Bosch<sup>b,f</sup>, Mario Poljak<sup>c</sup>, Dur-e-Nayab Waheed<sup>a</sup>, Margaret Stanley<sup>d</sup>, Suzanne M. Garland<sup>e</sup>, on behalf of the HPV Prevention and Control Board and the International Papillomavirus Society (IPVS)

<sup>a</sup> Center for the Evaluation of Vaccination & HPV Prevention and Control Board, University of Antwerp, Antwerp, Belgium

<sup>b</sup> Cancer Epidemiology Research Program, IDIBELL, Catalan Institute of Oncology, L'Hospitalet De Llobregat, Barcelona, Spain

<sup>c</sup> Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

<sup>d</sup> Department of Pathology, University of Cambridge, United Kingdom

<sup>e</sup> Department of Obstetrics and Gynaecology, University of Melbourne, Centre Women's Infectious Diseases Research, Royal Women's Hospital, Murdoch Children's Research Institute, Australia

<sup>f</sup> Open University of Catalonia, Barcelona, Spain

### ARTICLE INFO

#### Keywords

HPV  
Prevention and control  
Cervical cancer  
COVID-19 pandemic  
Elimination  
Screening  
Vaccination

### ABSTRACT

The global confrontation with COVID-19 has not only diverted current healthcare resources to deal with the infection but has also resulted in increased resources in the areas of testing and screening, as well as educating most of the global public of the benefits of vaccination. When the COVID-19 pandemic eventually recedes, the opportunity must not be missed to ensure that these newly created resources are maintained and redeployed for use in testing and immunisation against other vaccine-preventable infectious diseases. A notable example is infection by human papillomavirus (HPV), the commonest sexually transmitted human virus and the leading cause of a variety of cancers in both men and women, such as cervical, head and neck, anal, vaginal, vulvar and



- Dissemination to scientific network through social channels including:

- HPV Board Newsletter
- Twitter/Linked In
- Webpage



- Publication of meeting proceedings in peer-reviewed journals.





HPV Prevention  
and Control Board

[www.hpvboard.org](http://www.hpvboard.org)

Technical Meeting:  
Accelerating HPV-related Cancer  
Elimination and HPV Faster  
6 – 7 June 2024  
Antwerp, Belgium



# Very interactive exchange while setting the agenda for this meeting.

- It is important to have an update on treatment. It is unclear if and how investments are devoted to improving treatment if groups like ours do not even address it openly.
- Discuss the concept of local calibration of targets and how to design other thresholds in a way to encourage intervention
- It is great time to revisit the WHO's call (90 70 90) and help countries doing the calibration of the target indicators to their circumstances
- What is the purpose of the twilight zone session? I would prefer to discuss reproducible science. Irreproducible results are not relevant to the subject.
- I would focus the title on acceleration-- I see FASTER as one technique to possibly do so, but maybe there are other approaches. The main meeting point is how do we get to elimination sooner.



# Preliminary Meeting Objectives (1)

- Key Considerations for accelerating elimination of HPV-related cancer strategies
  - Analyze the current status of WHO Elimination Goals on a global scale and identify opportunities for acceleration of cervical cancer prevention.
  - Present and discuss strategies to accomplish the goal of acceleration of prevention of cancer caused by HPV, such as HPV FASTER and HPV EVEN FASTER.
  - Identify research methodologies to gather evidence on HPV transmission prevention.



## Preliminary Meeting Objectives (2)

- Feasibility and cost-effectiveness of cancer prevention acceleration strategies
  - Identify essential factors for countries to consider when adopting cervical cancer accelerated elimination, such as cervical cancer screening coverage, screening platforms, vaccination strategies, and epidemiological data for program customization.
  - Define the optimal maximum age for HPV vaccination and related determinants
  - Explore the utility of modeling studies in refining and advancing these programs.
  - Analyze the influence of vaccine pricing, dosing, and scheduling on cervical cancer accelerated elimination cost-effectiveness, and propose optimization strategies.



## Preliminary Meeting Objectives (3)

- Evaluation of accelerated cervical cancer elimination strategies.
  - Discuss methods to measure both the goal indicators and cost-effectiveness of accelerated cervical cancer elimination initiatives.
  - Deliberate on specific resource-stratified requirements at the country level for implementation of accelerated cervical cancer elimination.
- Assessment of HPV FASTER Implementation Across Countries
  - Review the needs assessment procedures that led to the adoption of HPV FASTER in different countries, highlighting lessons learned and best practices.
- Understand the next steps and future research needs/gaps for these strategies



# Practical Announcements

**Please note that it's a hybrid meeting – we will appreciate that online and physical participants respect the time.**

## **Physical Participants**

- There are mics on each table. Please use the mic on your table to ask the question. It will help the online participants to follow the questions and discussion in the meeting room

## **Online Participants**

- Please switch on your video while introducing yourself and every time you speak
- Keep yourself on mute when not speaking
- Please make use of the chat function to ask any burning questions/comments or observations.

## **Physical and Online Participants**

- We will open the breakout rooms closer to the session time and ask you to choose one based on your expertise and interest. We will appreciate that you keep your video on during the breakout group session, if your internet connection is stable.
- Breakout group chairs: please ensure that online and physical participants get the opportunity to share their experience





## Topics for break out sessions:

- Tomorrow, we will set up three break-out groups.
  - The topics of these break-out groups are still to be defined based on the most pressing outcome of today's discussions.
- Please give your suggestions:
  - Use flipcharts
  - Use chat of Zoom meeting
  - Just tell us.

